Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

Major Program
Supportive Care and Symptom Management
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
SWOG Cancer Research Network
Recruiting ID
For more information, see NCT04871542
This study examines how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is the type of treatment that helps the body's immune system fight cancer. In the future, this information may help doctors make better decisions about cancer treatments.
Biospecimen Collection, Questionnaire Administration
Malignant Solid Neoplasm
Krishna S Gunturu, Debra M. Prow, Site Public Contact

See list of participating sites